CardioSource WorldNews | Page 59

ConfidEnCE
dEliVEREd.
ThE dATA
iS ClEAR.
HigH
suRViVal
at 1 yEaR.

93.3

%

*

CoreValve®
Evolut® R CE study
Extreme and
High Risk Patients

Recapturability backed by exceptional performance and
real-world outcomes. That’s meaningful innovation.

*Manoharan, G; Clinical Outcomes at 1 Year with a Repositionable
Self-Expanding Transcatheter Aortic Valve. Presented at the
Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting,
October 12, 2015.
N = 60

medtronic.com

|

EvolutR.com

201606259EN ©2016 Medtronic. All rights reserved. 2/2016

CoreValve® Evolut® R
TAVR System